Home Combat Arthritis Regeneron, Sanofi arthritis drug fails late-stage study in COVID-19 patients – Reuters

Regeneron, Sanofi arthritis drug fails late-stage study in COVID-19 patients – Reuters

Jul 04, 2020 comments off

Regeneron, Sanofi arthritis drug fails late-stage study in COVID-19 patients – Reuters

Regeneron Pharmaceuticals Inc and Sanofi said on Thursday their rheumatoid arthritis drug Kevzara failed to meet the main goals of a late-stage study testing it in COVID-19 patients.

Read More…

You May Also Like

Is Arthritis Pain Relief as Close as Your Spice Rack?

Scientists develop mathematical index to distinguish healthy microbiome from diseased

Flu outbreaks may be linked to COVID-19; arthritis drug benefit seen

COVID-19 roundup: Flu may be linked with coronavirus spread, RA drug could aid recovery | Daily Sabah – Daily Sabah

Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments

Roche says its drugs reduce ventilator need for COVID-19 patients – Reuters UK